Innovative erythrocyte-based carriers for gene delivery in porcine vascular smooth muscle cells: Basis for local therapy to prevent restenosis

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 12, Issue 1, 2012, Pages 68-75

  Lande, Caterina ^a   Cecchettini, Antonella ^a,d   Tedeschi, Lorena ^a   Taranta, Monia ^b   Naldi, Ilaria ^b   Citti, Lorenzo ^a   Trivella, Maria Giovanna ^a   Grimaldi, Settimio ^c   Cinti, Caterina ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b CNR   (Italy)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Biotherapy delivery; DNA oligonucleotide decoy; Erythrocyte based drug delivery system; Gene therapy; Target therapy; Vascular smooth muscle cells

Indexed keywords

GROWTH FACTOR; OLIGONUCLEOTIDE; SYNTHETIC DNA; TRANSCRIPTION FACTOR ELK 1;

ANIMAL CELL; ARTERY WALL; ARTICLE; CELL ENGINEERING; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG BIOAVAILABILITY; DRUG ELUTING STENT; ERYTHROCYTE BASED GENE DELIVERY SYSTEM; FEASIBILITY STUDY; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; LOCAL THERAPY; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PATENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN PHOSPHORYLATION; RESTENOSIS; SWINE; TARGET CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL GROWTH PROCESSES; CORONARY RESTENOSIS; DNA; ERYTHROCYTES; ETS-DOMAIN PROTEIN ELK-1; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; MICROSCOPY, CONFOCAL; MUSCLE, SMOOTH, VASCULAR; STENTS; SWINE;

EID: 84867523639     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152912801823101     Document Type: Article

References (44)

1. Morice, M-C.; Serruys, P.W.; Sousa, J.E.; Fajadet, J.F.; Hayashi E.B.; Perin, M.; Colombo, A.; Schuler, G.; Barragan, P.; Guagliumi, G.; Molnar, F.; Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med., 2002, 347, 561-6.
2. Sousa, J.E.; Serruyus P.W.; Costa M.A. New frontiers in cardiology: Drug-eluting stents: Part I. Circulation, 2003, 107, 2274-9.
3. Lerman, A.; Eeckhout, E. Coronary endothelial dysfunction following sirolimus-eluting stent placement: should we worry about it? Eur. Heart J., 2006, 27, 125-6.
4. Cook, S.; Ladich, E.; Nakazawa, G.; Eshtehardi, P.; Neidhart, M.; Vogel, R., Togni, M., Wenaweser, P., Billiger, M., Seiler, C., Gay, S., Meier, B., Pichler, W.J., Jüni, P., Virmani, R., Windecker, S. Correlation of Intravascular Ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation, 2009, 120, 391-399.
5. Schwartz, R.S.; Chronos, N.A.; Virmani R. Preclinical restenosis models and drug-eluting stents. Still important, still much to learn. J. Am. Coll. Cardiol., 2004, 44, 1373-1385.
6. Yazdani, S.K.; Kolodgie, F.D.; Virmani, R. Ex vivo and preclinical assessment of an endothelial progenitor cell capturing bioengineered stent. Minerva Cardioangiol., 2012, 60, 11-22.
7. Cecchettini, A.; Rocchiccioli, S.; Boccardi, C.; Citti, L. Vascular Smooth-Muscle-Cells activation: a proteomic point of view. Int. Rev. Cell Mol. Biol., 2011, 288, 43-99.
8. De Stefano, D.; De Rosa, G.; Carnuccio, R. NFkappaB decoy oligonucleotides. Curr. Opin. Mol. Ther., 2010, 12, 203-13.
9. Brennan, P.; Doney, R.; Hewamana, S. Targeting transcription factors for therapeutic benefit. Molecular Biosystems, 2008, 4, 909-919.
10. Kim, S-J.; Park, J-M.; Kim, K-H.; Lee, W-R.; Lee, S.; Kwon, O-C.; Kim, K-S.; Park, K-K. Effect of NFkB decoy oligonucleotide on LPS/High-fat diet-induced atherosclerosis in an animal model. Basic & Clin. Pharmacol. & Toxicol., 2010, 107, 925-930.
11. Peroulis, M.; Kakisis, J.; Kapelouzou, A.; Giagini, A.; Giaglis, S.; Mantziaras, G.; Kostomitsopoulos, N.; Karayannacos, P.; Macheras, A. The role of ex-vivo gene therapy of veingrafts with Egr-1 decoy in the suppression of intimal hyperplasia. Eur. J. Vasc. Endovasc. Surg., 2010, 40, 216-223.
12. Han, W.; Lin, G-N. Egr-1 decoy ODN inhibit vascular smooth muscle cell proliferation and intimal hyperplasia of balloon-injured arteries in rat. Life Sci., 2010, 86, 234-243.
13. Allen, T.M.; Cullis, P.R. Drug delivery systems: entering the mainstream. Science, 2004, 303, 1818-1822.
14. Agnihotri, S.A.; Mallikarjuna, N.N.; Aminabhavi, T.M. Recent advances on chitosan-based micro and nanoparticles in drug delivery. J. Control. Release, 2004, 100, 5-28.
15. Aminabhavi, T.M.; Soppimath, K.S.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradabile polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70, 1-20.
16. Roney, C.; Kulkarni, P.; Arora, V.; Antich, P.; Bonte, F.; Wu, A.; Mallikarjuana, N.N.; Manohar, S.; Liang, H.F.; Kulkarni, A.R.; Sung, H.W.; Sairam, M.; Aminabhavi, T.M. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control. Release, 2005, 108, 193-214.
17. Pierigè, F., Serafini, S., Rossi, L., Magnani, M. Cell-based drug delivery. Adv.DrugDeliv. Rev., 2008, 60, 286-295.
18. Cestmir, A. Pro drug cancer gene therapy. Cancer letter., 2008, 270, 191-201.
19. Gorantla, S.; Dou, H.; Boska, M.; Distache, C.; Nelson, J.; Rabinow, B.; Gendelman, H.E.; Mosley, R.L. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J. Leukoc. Biol., 2006, 80, 1165-1174.
20. Studeny, M.; Marini, F.C.; Dembinski, J.L.; Zompetta, C.; Cabreira-Hansen, M.; Bekele, B.N.; Champlin, R.E.; Andreef, M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst., 2004, 96, 1593-1603.
21. Studeny, M.; Marini, F.C.; Champlin, R.E.; Zompetta, C.; Fidler, I.J.; Andreeff, M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res., 2002, 62, 3603-3608.
22. Hamidi, M.; Zarrin, A.; Foroozesh, M.; Mohammadi-Samani, S. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J. Control. Release, 2007, 118, 145-160.
23. Rossi, L.; Serafini, S.; Pierigé, F.; Antonelli, A.; Cerasi, A.; Fraternale, A.; Chiarantini, L.; Magani, M. Erythrocyte-based drug delivery. Expert Opin. Drug Deliv., 2005, 2, 311-22.
24. Provotorov, V.M.; Ivanova, G.A. The role of erythrocytes in the system of controlled transport of pharmaceutical agents. Klin. Med., 2009, 87, 4-8.
25. Cinti, C.; Grimaldi, S.; Lisi, A. Erythrocyte-based delivery system, method of preparation and uses thereof. Inc WO2010070620 (A1). December 18, 2009.
26. Taranta, M.; Naldi, I.; Grimaldi, S.; Salvini L.; Claudio P.P.; Rocchio, F.; Munoz, A.F.; Prete, S.; Cinti, C. Magnetically driven bioreactors as new tools in drug delivery. J. Bioanal Biomed 2011, S5 E-pubb http://dx.doi.org/10.4172/1948-593X.S5-002
27. Cinti, C.; Taranta, M.; Naldi, I.; Grimaldi, S. Newly engineered magnetic erythrocytes for sustained and targeted delivery of anticancer therapeutic compounds. PLoS One, 2011, 6(2), e17132.
28. Janknecht, R.; Nordheim, A. Elk-1 protein domain required for direct and SRF-assisted DNA-Binding. Nucleic Acids Res, 1992, 20, 3317-3324.
29. Tamana, K.; Sen, C.K.; Wells, A. Differentiation of mesenchymal stem cells into the smooth muscle lineage by blocking ERK/MAP signaling pathway. Stem Cell Dev., 2008, 17, 897-908.
30. Christen, T.; Bochaton-Piallat, M.L.; Neuville, P.; Rensen, S.; Redard, M.; van Eys, G.; Gabbiani, G. Cultured porcine coronary artery smooth muscle cells - A new model with advanced differentiation. Cir. Res., 1999, 85, 99-107.
31. Horwitz, R.; Webb, D. Cell migration. Curr. Biol., 2003, 13, R756-9.
32. Ridley, A.J.; Schwartz, M.A.; Burridge, K.; Firtel, R.A.S.; Ginsberg, M.H.; Borisy, G.; Parson, J.T.; Horwitz, A.R. Cell Migration: Integrating Signals from Front to Back. Science, 2003, 302, 1704-09.
33. Kawai-Kowase, K.; Owens, G.K. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am. J. Physiol. Cell Physiol., 2007, 292, C59-C69.
34. Zhao, M.; Liu, Y.; Bao, M.; Kato, Y.; Han, J.; Eaton, J.W. Vascular smooth muscle cell proliferation requires p38 and BMK1 MAP kinases. Archives Biochem. Biophys., 2002, 400, 199-207.
35. Brennan, P.; Donev, R.; Hewamana, S. Targeting transcription factors for therapeutic benefit. Molecular Biosystems, 2008, 4, 909-19.
36. Gaglione, M.; Messere, A. Recent progress in chemically modified siRNAs. Mini Rev Med Chem., 2010, 10, 578-95.
37. Higuchi, Y.; Kawakami, S.; Hashida, M. Strategies for in vivo delivery of siRNAs: recent progress. Bio Drugs., 2010, 24, 195-205.
38. Tros de Ilarduya, C.; Sun, Y.; Düzgüneş, N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci., 2010, 40, 159-70.
39. Pharmacek, M.S. Myocardin-related Transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circ. Res., 2007, 1000, 633-644.
40. Tamama, K.; Sen, C.K.; Wells, A. Differentiation of Bone Marrow Mesenchymal Stem Cells into the Smooth Muscle Lineage by Blocking ERK/MAPK Signaling Pathway. Stem Cells Dev., 2008, 17, 897-908.
41. Hipskind, R.A.; Rao, V.N.; Mueller, C.G.; Reddy, E.S.; Nordheim, A. Ets-related protein Elk-1 is homologous to the c-fos regulator factor p62TCF. Nature, 1991, 354, 531-534.
42. Chai, Y.; Chipitsyna, G.; Cui, J.; Liao, B.; Liu, S.; Aysola, K.; Yezdani, M.; Reddy, E.S.; Rao, V.N. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. Oncogene, 2001, 20, 1357-67.
43. Merdan, T.; Kopecek, J.; Kissel, T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer, Adv Drug Deliv., 2002, 54, 715-58.
44. Mahmoodzadeh, S., Dworatzek, E.; Fritschka, S., Pham, T.H., Regitz-Zagrosek, V. 17β-Estradiol inhibits matrix metalloproteinase- 2 transcription via MAP kinase in fibroblasts. Cardiovascular Res., 2010, 85, 719-728.